Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
Avadel Pharmaceuticals May 1 2023 PDF https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-announces-final-fda-appro...